In mouse models of AML, the combination of NVP-LDE225 and doxorubicin demonstrates significant anti-tumor effects, potentially related to the inhibition of the Hh/IGF-IR/Akt/MRP1 pathway (192). The gene discussed is AKT1; the disease is acute myeloid leukemia.